Has anyone tried running beyond the 2x250bp "official" capacity of the MiSeq? We worked with a sequencing collaborator who hacked together a 2x250 run before the reagents were available by unofficially (although aided by Illumina tech support) pooling a 2x150 and a 1x100 cartridge. Any idea if pooling of a 2x250 and a 2x150 is possible, allowing early access to the supposedly upcoming 2x400 run?
-
-
I'm not sure you would want to try that yet.
see posts below.
-
2 x 250 runs are not stably working (in our hands) as yet. Perhaps others have had better luck. No problems getting sequence, it is the decline in quality over the later cycles.
Hopefully this is just teething troubles that will get sorted out over time.
If you have the time (and money) to try the 2 x 400, go right ahead. Let us know what happens.Comment
-
Is this with a hardware-upgraded instrument? Does going to lower loading densities appear to help?Originally posted by GenoMax View Post
--
PhillipComment
-
"Illumina are testing 400bp single-end reads in R&D on the MiSeq, with the longest achieved overlapping paired-read of 678bp"
I think I read somewhere that it was around 80% >Q20 @ 400bpComment
-
Yes. Our instrument has received the hardware upgrade.Originally posted by pmiguel View Post
Not sure. v.1. runs (2 x 25 bp) are looking fine, it is the v.2. runs (2 x 250 bp) that seem to be the problem. We have done two long runs so far (one sample and one phiX).Does going to lower loading densities appear to help?
--
Phillip
We are working with illumina at the moment. This may be a specific issue with our instrument. We shall see.Comment
-
Tumors contain complex mixtures of cell populations that evolve in response to treatment and host-specific factors. Tissue biopsies provide only static snapshots of a tumor’s state. But what if we could follow that evolution over time using a minimally invasive technique?
Liquid biopsies can detect tumor-derived material circulating in the bloodstream, providing a way to study treatment response, detect emerging resistance, and discover new biomarkers. Circulating...10-14-2026, 09:55 AM -
Researchers using sequencing and genomics tools often have to make trade-offs. They can choose between speed or scale, short reads or long-range information, or targeted panels or a view of the whole transcriptome. New technologies that have been released this year are built to address those tough choices.
We asked six companies the same four questions to learn about their latest products. The new technologies bring a lot to the table, including rethinking sequencing...
Comment